BioMarin should be bought on weakness if it scraps BMN-701, says RBC Capital

RBC Capital recommends buying BioMarin on weakness if the company chooses not to proceed with the development of its BMN-701 drug after reporting Phase II data on February 15, as the firm thinks that the drug isn't key to the company's success. The firm remains upbeat on BioMarin's outlook and reiterates an Outperform rating.

View Comments (0)